ADC Therapeutics

Home » ADC Therapeutics

IPO

ADC Therapeutics

Biotechnology

We are a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (“ADCs”) for patients suffering from hematological malignancies and solid tumors.

Symbol

ADCT

Price Range
$23.00 - $26.00

Final Shares
8,164,000

Anticipated Date
October 3, 2019

Underwriters
MORGAN STANLEY & CO. LLC,MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED

This offering is no longer available

To view the prospectus for ADC Therapeutics IPO, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253